CD5 CAR T (CT125B)
/ Beijing Boren Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 14, 2024
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Beijing Boren Hospital | N=18 ➔ 0 | Trial completion date: Jul 2024 ➔ Dec 2023 | Recruiting ➔ Withdrawn | Trial primary completion date: Jul 2024 ➔ Dec 2023
Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • CD5
August 04, 2022
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: Beijing Boren Hospital
New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • CD5
1 to 2
Of
2
Go to page
1